4.85 USD
+0.12 (+2.54%)
Taking everything into account, GNFT scores 2 out of 10 in our fundamental rating. GNFT was compared to 530 industry peers in the Biotechnology industry. GNFT may be in some trouble as it scores bad on both profitability and health. GNFT is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
GNFT had negative earnings in the past year.
In the past year GNFT has reported a negative cash flow from operations.
In multiple years GNFT reported negative net income over the last 5 years.
In multiple years GNFT reported negative operating cash flow during the last 5 years.
1.2 Ratios
GNFT's Return On Assets of -17.89% is fine compared to the rest of the industry. GNFT outperforms 78.13% of its industry peers.
GNFT has a Return On Equity (-73.87%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.89% | ||
| ROE | -73.87% | ||
| ROIC | N/A |
ROA(3y)-8.87%
ROA(5y)-10.74%
ROE(3y)-21.81%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
GNFT's Profit Margin has declined in the last couple of years.
In the last couple of years the Operating Margin of GNFT has declined.
GNFT has a Gross Margin of 95.42%. This is amongst the best in the industry. GNFT outperforms 94.95% of its industry peers.
In the last couple of years the Gross Margin of GNFT has remained more or less at the same level.
GNFT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 95.42% |
OM growth 3Y-50.59%
OM growth 5YN/A
PM growth 3Y-69.99%
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y0.52%
2. Health
2.1 Basic Checks
GNFT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, GNFT has more shares outstanding
GNFT has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, GNFT has a worse debt to assets ratio.
2.2 Solvency
GNFT has an Altman-Z score of -1.41. This is a bad value and indicates that GNFT is not financially healthy and even has some risk of bankruptcy.
GNFT's Altman-Z score of -1.41 is in line compared to the rest of the industry. GNFT outperforms 52.52% of its industry peers.
A Debt/Equity ratio of 0.09 indicates that GNFT is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.09, GNFT is doing worse than 63.55% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.41 |
ROIC/WACCN/A
WACC7.22%
2.3 Liquidity
GNFT has a Current Ratio of 3.74. This indicates that GNFT is financially healthy and has no problem in meeting its short term obligations.
GNFT has a Current ratio (3.74) which is comparable to the rest of the industry.
A Quick Ratio of 3.74 indicates that GNFT has no problem at all paying its short term obligations.
With a Quick ratio value of 3.74, GNFT perfoms like the industry average, outperforming 46.73% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.74 | ||
| Quick Ratio | 3.74 |
3. Growth
3.1 Past
GNFT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -289.19%.
Measured over the past years, GNFT shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -70.77% on average per year.
GNFT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -45.94%.
Measured over the past years, GNFT shows a quite strong growth in Revenue. The Revenue has been growing by 11.61% on average per year.
EPS 1Y (TTM)-289.19%
EPS 3Y-70.77%
EPS 5YN/A
EPS Q2Q%-137.74%
Revenue 1Y (TTM)-45.94%
Revenue growth 3Y-6.06%
Revenue growth 5Y11.61%
Sales Q2Q%-43.21%
3.2 Future
Based on estimates for the next years, GNFT will show a very negative growth in Earnings Per Share. The EPS will decrease by -29.44% on average per year.
Based on estimates for the next years, GNFT will show a decrease in Revenue. The Revenue will decrease by -1.86% on average per year.
EPS Next Y-192.65%
EPS Next 2Y-96.29%
EPS Next 3Y-45.26%
EPS Next 5Y-29.44%
Revenue Next Year-34.41%
Revenue Next 2Y-21.93%
Revenue Next 3Y-9.85%
Revenue Next 5Y-1.86%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for GNFT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GNFT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
GNFT's earnings are expected to decrease with -45.26% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-96.29%
EPS Next 3Y-45.26%
5. Dividend
5.1 Amount
GNFT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:GNFT (11/19/2025, 2:00:00 PM)
4.85
+0.12 (+2.54%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners0.73%
Inst Owner Change0%
Ins Owners0.18%
Ins Owner ChangeN/A
Market Cap242.51M
Revenue(TTM)45.41M
Net Income(TTM)-38.76M
Analysts90.77
Price Target9.84 (102.89%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.43%
PT rev (3m)-8.49%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-766.16%
EPS NY rev (3m)-159.86%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-28.49%
Revenue NY rev (3m)-29.85%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 4.59 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.97 | ||
| P/tB | 97.96 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.81
EYN/A
EPS(NY)-0.79
Fwd EYN/A
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS1.06
BVpS1.22
TBVpS0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.89% | ||
| ROE | -73.87% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 95.42% | ||
| FCFM | N/A |
ROA(3y)-8.87%
ROA(5y)-10.74%
ROE(3y)-21.81%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-50.59%
OM growth 5YN/A
PM growth 3Y-69.99%
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y0.52%
F-Score2
Asset Turnover0.21
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 188.46% | ||
| Cap/Sales | 7.33% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.74 | ||
| Quick Ratio | 3.74 | ||
| Altman-Z | -1.41 |
F-Score2
WACC7.22%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-289.19%
EPS 3Y-70.77%
EPS 5YN/A
EPS Q2Q%-137.74%
EPS Next Y-192.65%
EPS Next 2Y-96.29%
EPS Next 3Y-45.26%
EPS Next 5Y-29.44%
Revenue 1Y (TTM)-45.94%
Revenue growth 3Y-6.06%
Revenue growth 5Y11.61%
Sales Q2Q%-43.21%
Revenue Next Year-34.41%
Revenue Next 2Y-21.93%
Revenue Next 3Y-9.85%
Revenue Next 5Y-1.86%
EBIT growth 1Y-216.85%
EBIT growth 3Y-53.58%
EBIT growth 5YN/A
EBIT Next Year-284.52%
EBIT Next 3Y-33.99%
EBIT Next 5YN/A
FCF growth 1Y87.25%
FCF growth 3Y-47.27%
FCF growth 5YN/A
OCF growth 1Y93.33%
OCF growth 3Y-46.21%
OCF growth 5YN/A
GENFIT-ADR / GNFT FAQ
What is the fundamental rating for GNFT stock?
ChartMill assigns a fundamental rating of 2 / 10 to GNFT.
What is the valuation status for GNFT stock?
ChartMill assigns a valuation rating of 0 / 10 to GENFIT-ADR (GNFT). This can be considered as Overvalued.
Can you provide the profitability details for GENFIT-ADR?
GENFIT-ADR (GNFT) has a profitability rating of 2 / 10.
What is the expected EPS growth for GENFIT-ADR (GNFT) stock?
The Earnings per Share (EPS) of GENFIT-ADR (GNFT) is expected to decline by -192.65% in the next year.